Zamann Pharma Support logo

Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Request an appointment now

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

News and more

Data Safety Monitoring in Pharma in 2026: DSMB Oversight Risk Signals and Trial Decisions

Explore how DSMBs review safety signals, assess benefit risk, manage interim analyses, and document trial decisions. This guide explains the evidence, controls, and inspection-ready records pharmaceutical teams need to strengthen clinical trial oversight and support regulatory compliance
  • Blog, Quality Management System
Data Monitoring Committee bei der Prüfung von Sicherheitszwischendaten, Nutzen-Risiko-Bewertung und Überwachung klinischer Studien in einem pharmazeutischen Umfeld.

Data Analytics in Pharmacovigilance in 2026: Turning Safety Data Into Faster Regulatory Decisions

Explore how modern safety teams use signal detection, real-world evidence, AI, and controlled review processes to turn complex safety information into traceable regulatory decisions. The article explains practical methods, inspection expectations, and governance controls for stronger pharmacovigilance oversight.
  • Blog, Computerized System Validation
Fachkraft für Arzneimittelsicherheit bei der Auswertung digitaler Dashboards für Drug Safety Surveillance, Signalbewertung und globale regulatorische Überwachung.

Harmonization in Pharmacovigilance in 2026: Global Regulations, ICSR Reporting and ICH Standard

Drug safety requirements vary across regions, making consistent reporting a complex task for global teams. This article explains key regulatory expectations, ICH guidelines, ICSR reporting, MedDRA terminology, and practical considerations for maintaining compliant safety reporting worldwide.
  • Blog, Quality Management System
Digitales globales Netzwerk zur Darstellung von Arzneimittelsicherheitsmeldungen, ICSR-Berichterstattung und regulatorischer Koordination zwischen mehreren Ländern.

Causality Assessment in Pharmacovigilance in 2026: WHO-UMC Naranjo and ICSR Decision Framework

Learn how pharmacovigilance teams evaluate suspected adverse drug reactions using structured approaches, including WHO UMC causality assessment, Naranjo scale principles, and clinical evidence review. Discover how temporal relationship, dechallenge, rechallenge, and alternative causes influence safety decisions.
  • Blog, Quality Management System
Pharmakovigilanz-Fachkraft analysiert Daten zu unerwünschten Arzneimittelwirkungen mit Hilfe von Kausalitätsbewertungstools wie der WHO-UMC-Kausalitätsbewertung und klinischer Evidenzbewertung.

Aggregate Reporting in Pharmacovigilance in 2026: PSUR PBRER DSUR Timelines and Regulatory Expectations

Understand how PSUR, PBRER, and DSUR support safety oversight across the product lifecycle. This guide explains reporting timelines, data lock points, reconciliation controls, benefit-risk assessment, and inspection expectations to help pharmacovigilance teams strengthen compliance and reporting quality.
  • Blog, Quality Management System
Pharmakovigilanz-Reporting-Dashboard mit Sicherheitstrends, Fallverteilung, Datenquellen, Signalbewertung und Nutzen-Risiko-Bewertung.

Good Pharmacovigilance Practice (GVP) in 2026: What PV Teams Must Know About Compliance and Inspections

Understand how GVP modules shape pharmacovigilance systems, inspections, QPPV oversight, audits, risk management, and signal activities. This guide explains what regulators expect, which records matter most, and how PV teams can maintain practical, inspection-ready compliance.
  • Blog, Quality Management System
Digitales Pharmakovigilanz-Dashboard mit Darstellung von Signalmanagement, Compliance-Status, Inspektionsbereitschaft und globaler Sicherheitsüberwachung.

Types of Pharmacovigilance in 2026: Active Passive and Targeted Drug Safety Monitoring

Effective drug safety depends on choosing the right monitoring approach. This article explains active and passive systems, spontaneous reporting, targeted follow-up, and post-marketing studies, while showing how each method supports signal detection, compliance, and inspection readiness.
  • Blog, Quality Management System
Pharmaceutical safety team reviewing adverse drug reactions, signal detection data, and post marketing surveillance dashboards.

Scope of Pharmacovigilance in 2026: Drug Safety Roles Skills and Career Growth

Explore how drug safety teams manage ICSRs, signals, risks, inspections, and regulatory responsibilities. This article also explains key pharmacovigilance jobs, required skills, career progression, and the evidence companies need to maintain strong compliance.
  • Blog, Quality Management System
Ein Arzneimittelsicherheitsteam überprüft Nebenwirkungsmeldungen, Daten zur Signalerkennung und Dashboards zur Überwachung nach der Marktzulassung.